IGEA Pharma NV
SIX:IGPH

Watchlist Manager
IGEA Pharma NV Logo
IGEA Pharma NV
SIX:IGPH
Watchlist
Price: 0.0005 CHF Market Closed
Market Cap: CHf505.5k

IGEA Pharma NV
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

IGEA Pharma NV
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
IGEA Pharma NV
SIX:IGPH
Research & Development
-€13.4k
CAGR 3-Years
52%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
O
ONWARD Medical NV
XBRU:ONWD
Research & Development
-€17.2m
CAGR 3-Years
-4%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
No Stocks Found

IGEA Pharma NV
Glance View

Market Cap
505.5k CHF
Industry
Health Care

IGEA Pharma NV is a health-tech company focused on measure and control of test factors related to life-threatening diseases. The company is headquartered in Hoofddorp, Noord-Holland. The company went IPO on 2018-12-20. The firm focuses on research and development of biomedical solutions for the prevention of diabetes and Alzheimer's disease. Its offering portfolio includes medical testing devices and dietary supplements. The firm develops ALZ-1 Test, a blood test to measure and control level of free copper, also known as Free Copper II or Non-Ceruloplasmin Copper in the bloodstream, which is a major recognized modifiable risk factor for the Alzheimer’s disease. The firm offers its services in the Netherlands.

IGPH Intrinsic Value
Not Available

See Also

What is IGEA Pharma NV's Research & Development?
Research & Development
-13.4k EUR

Based on the financial report for Dec 31, 2022, IGEA Pharma NV's Research & Development amounts to -13.4k EUR.

What is IGEA Pharma NV's Research & Development growth rate?
Research & Development CAGR 3Y
52%

Over the last year, the Research & Development growth was 91%. The average annual Research & Development growth rates for IGEA Pharma NV have been 52% over the past three years .

Back to Top